Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib with chemotherapy in pediatric relapsed or resistant Philadelphia chromosome-positive acute lymphoblastic leukemia
NL-OMON55917Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by Takeda. Planned start Dec 2020; status: withdrawn.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NL-OMON55917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55917.